AXNX Axonics Inc
Price (delayed)
$69
Market cap
$3.53B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.02
Enterprise value
$3.37B
Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers
Highlights
AXNX's EPS has soared by 97% year-on-year and by 94% since the previous quarter
The net income has soared by 95% YoY and by 89% from the previous quarter
AXNX's quick ratio is down by 38% year-on-year and by 11% since the previous quarter
The company's debt rose by 2.7% QoQ
Key stats
What are the main financial stats of AXNX
Market
Valuations
Earnings
Shares outstanding
51.12M
Market cap
$3.53B
Enterprise value
$3.37B
Price to earnings (P/E)
N/A
Price to book (P/B)
5.47
Price to sales (P/S)
8.44
EV/EBIT
1,543.41
EV/EBITDA
229.19
EV/Sales
8.25
Revenue
$408.81M
EBIT
$2.19M
EBITDA
$14.71M
Free cash flow
$18.92M
Per share
Balance sheet
Liquidity
EPS
-$0.02
Free cash flow per share
$0.38
Book value per share
$12.61
Revenue per share
$8.17
TBVPS
$11.44
Total assets
$747.34M
Total liabilities
$104.02M
Debt
$32.45M
Equity
$643.32M
Working capital
$454.89M
Debt to equity
0.05
Current ratio
8.96
Quick ratio
7.33
Net debt/EBITDA
-10.52
Margins
Efficiency
Dividend
EBITDA margin
3.6%
Gross margin
75.9%
Net margin
-0.4%
Operating margin
-3.7%
Return on assets
-0.2%
Return on equity
-0.3%
Return on invested capital
0.7%
Return on capital employed
0.3%
Return on sales
0.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXNX stock price
How has the Axonics stock price performed over time
Intraday
0.15%
1 week
0.39%
1 month
0.25%
1 year
17.93%
YTD
10.88%
QTD
2.63%
Financial performance
How have Axonics's revenue and profit performed over time
Revenue
$408.81M
Gross profit
$310.26M
Operating income
-$15.12M
Net income
-$1.71M
Gross margin
75.9%
Net margin
-0.4%
The company's net margin has surged by 96% YoY and by 90% QoQ
The net income has soared by 95% YoY and by 89% from the previous quarter
The operating margin has surged by 74% year-on-year and by 54% since the previous quarter
The company's operating income has surged by 67% YoY and by 51% QoQ
Growth
What is Axonics's growth rate over time
Valuation
What is Axonics stock price valuation
P/E
N/A
P/B
5.47
P/S
8.44
EV/EBIT
1,543.41
EV/EBITDA
229.19
EV/Sales
8.25
AXNX's EPS has soared by 97% year-on-year and by 94% since the previous quarter
AXNX's equity is up by 7% year-on-year and by 2.6% since the previous quarter
The P/B is 7% above the last 4 quarters average of 5.1 but 4.2% below the 5-year quarterly average of 5.7
The price to sales (P/S) is 65% lower than the 5-year quarterly average of 24.3
The revenue has increased by 28% year-on-year and by 6% since the previous quarter
Efficiency
How efficient is Axonics business performance
AXNX's ROIC has soared by 116% QoQ and by 105% YoY
AXNX's ROS has soared by 114% since the previous quarter and by 105% year-on-year
AXNX's ROA has soared by 96% YoY and by 91% from the previous quarter
The ROE has soared by 95% YoY and by 88% from the previous quarter
Dividends
What is AXNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXNX.
Financial health
How did Axonics financials performed over time
The total liabilities has surged by 115% year-on-year and by 18% since the previous quarter
AXNX's quick ratio is down by 38% year-on-year and by 11% since the previous quarter
The company's debt is 95% lower than its equity
AXNX's equity is up by 7% year-on-year and by 2.6% since the previous quarter
The company's debt rose by 2.7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.